Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 ...
Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...
Andrew Hillman Grant for Biotech Introduces National Opportunity for Undergraduate Talent to Explore the Future of ...
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...
BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...
Fermentation has evolved from a traditional preservation method into a cornerstone of modern food innovation, where the intersection of bioprocess ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results